Suppr超能文献

先采用手术或生长抑素类似物治疗肢端肥大症对心肌病的影响。

Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy.

作者信息

Colao Annamaria, Pivonello Rosario, Galderisi Maurizio, Cappabianca Paolo, Auriemma Renata S, Galdiero Mariano, Cavallo Luigi M, Esposito Felice, Lombardi Gaetano

机构信息

Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, via S. Pansini 5, Naples, Italy.

出版信息

J Clin Endocrinol Metab. 2008 Jul;93(7):2639-46. doi: 10.1210/jc.2008-0299. Epub 2008 Apr 29.

Abstract

OBJECTIVE

The objective of the study was to investigate whether first-line surgery or somatostatin analogs (SSA) have a different outcome on cardiomyopathy after 12 months.

DESIGN

This was a retrospective, comparative, nonrandomized study.

PATIENTS

Fifty-six patients treated with SSA and 33 operated on by transsphenoidal approach participated in the study. For the purposes of this study, only controlled patients were included.

MEASUREMENTS

Primary outcome measures were changes in left ventricular mass index, diastolic (early to atrial mitral flow velocity), and systolic performance (left ventricular ejection fraction). Secondary outcome measures were reduction of total to high-density lipoprotein-cholesterol ratio as a cardiovascular risk parameter, and improvement of glucose profile and pituitary function as indirect causes of cardiovascular improvement.

RESULTS

SSA and surgery groups were similar for gender, age, estimated disease duration, GH and IGF-I levels, and severity of cardiomyopathy lipid and glucose profile. Twelve months after treatment in both groups, left ventricular mass index, early to atrial mitral flow velocity, diastolic blood pressure, and heart rate decreased significantly, whereas only in SSA-treated patients, left ventricular ejection fraction increased significantly. The total to high-density lipoprotein-cholesterol ratio significantly reduced only in SSA-treated patients, whereas fasting glucose levels significantly decreased only in surgery-treated patients. A normal pituitary function was found in 46.4% of SSA- and 36.4% of surgery-treated patients, with results unchanged in the former and slightly reduced in the latter.

CONCLUSIONS

Twelve months after first-line treatment with SSA or surgery, we found a similar improvement in left ventricular hypertrophy and diastolic filling. In contrast, systolic function improved more evidently in SSA-treated patients. Both a direct effect of SSA and a more preserved pituitary function might explain these results.

摘要

目的

本研究的目的是调查一线手术或生长抑素类似物(SSA)在12个月后对心肌病是否有不同的疗效。

设计

这是一项回顾性、比较性、非随机研究。

患者

56例接受SSA治疗的患者和33例经蝶窦入路手术的患者参与了本研究。为了本研究的目的,仅纳入病情得到控制的患者。

测量指标

主要结局指标为左心室质量指数、舒张功能(二尖瓣早期与心房血流速度)和收缩功能(左心室射血分数)的变化。次要结局指标为作为心血管风险参数的总胆固醇与高密度脂蛋白胆固醇比值的降低,以及作为心血管改善间接原因的血糖谱和垂体功能的改善。

结果

SSA组和手术组在性别、年龄、估计病程、生长激素和胰岛素样生长因子-I水平以及心肌病的脂质和血糖谱严重程度方面相似。两组治疗12个月后,左心室质量指数、二尖瓣早期与心房血流速度、舒张压和心率均显著下降,而仅接受SSA治疗的患者左心室射血分数显著增加。仅在接受SSA治疗的患者中,总胆固醇与高密度脂蛋白胆固醇比值显著降低,而仅在接受手术治疗的患者中,空腹血糖水平显著下降。46.4%的SSA治疗患者和36.4%的手术治疗患者垂体功能正常,前者结果未变,后者略有下降。

结论

在使用SSA或手术进行一线治疗12个月后,我们发现左心室肥厚和舒张期充盈有相似的改善。相比之下,接受SSA治疗的患者收缩功能改善更明显。SSA的直接作用和更保留的垂体功能可能解释了这些结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验